Skip to main content
. 2016 Dec 3;8(5):7559–7571. doi: 10.18632/oncotarget.13791

Figure 7. The in vitro effects of etanercept and adalimumab on Th17-related cytokine production by Th17-polarized cells from an RA patient undergoing Enbrel™ treatment.

Figure 7

Th17-polarized cells induced from CD4+ T cells that were collected from an RA patient 2 h before (at the trough level) and 48 h after (at the peak level) of Enbrel™ injection. The in vitro effects of etanercept (1 μg/mL) and adalimumab (1 and 10 μg/mL) on IL-17A, IL-17F and IL-22 production in Th17-polarized cells were determined by ELISA. P-values indicate comparison of the cytokine levels before and after Enbrel™ injection. (A) IL-17A production by Th17-polarized cells isolated from the RA patient 2 h before and 48 h after Enbrel™ injection was significantly suppressed by in vitro treatment with adalimumab (1 and 10 μg/mL) but not etanercept (1 μg/mL). (B) IL-17F and (C) IL-22 production was significantly suppressed by in vitro treatment with etanercept (1 μg/mL) and adalimumab (1 μg/mL) when cells were isolated from the RA patient 2 h before but not 48 h after Enbrel™ injection. In vitro pretreatment with adalimumab (10 μg/mL) significantly suppressed IL-17F and IL-22 production both before and after Enbrel™ injection. The bars represent the means ± standard deviations from three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 between the Th17-polarized cells with and without in vitro etanercept or adalimumab pretreatment.